Hayley B Gershengorn1, Adam Keene1, Amy L Dzierba2, Hannah Wunsch3. 1. Division of Critical Care Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx. 2. Department of Pharmacy, Columbia University, New York Presbyterian Hospital, New York. 3. Department of Critical Care Medicine, Sunnybrook Health Sciences Center, Toronto Department of Anesthesiology Interdepartmental Division of Critical Care, University of Toronto, Ontario, Canada Department of Anesthesiology, Columbia University, New York, New York.
Abstract
BACKGROUND: Guidelines recommend azithromycin or a quinolone antibiotic for treatment of Legionella pneumonia. No clinical study has compared these strategies. METHODS: We performed a retrospective cohort analysis of adults hospitalized in the United States with a diagnosis of Legionella pneumonia in the Premier Perspectives database (1 July 2008-30 June 2013). Our primary outcome was hospital mortality; we additionally evaluated hospital length of stay, development of Clostridium difficile colitis, and total hospital cost. We used propensity-based matching to compare patients treated with azithromycin vs a quinolone. All analyses were repeated on a subgroup of more severely ill patients, defined as requiring intensive care unit admission or mechanical ventilation or having a predicted probability of hospital mortality in the top quartile for all patients. RESULTS: Legionella pneumonia was diagnosed in 3152 adults across 437 hospitals. Quinolones alone were used in 28.8%, azithromycin alone was used in 34.0%, and 1.8% received both. Crude hospital mortality was similar: 6.6% (95% confidence interval [CI], 5.0%-8.2%) for quinolones vs 6.4% (95% CI, 5.0%-7.9%) for azithromycin (P = .87); after propensity matching (n = 813 in each group), mortality remained similar (6.3% [95% CI, 4.6%-7.9%] vs 6.5% [95% CI, 4.8%-8.2%], P = .84 for the whole cohort, and 14.9% [95% CI, 10.0%-19.8%] vs 18.3% [95% CI, 13.0%-23.6%], P = .36 for the more severely ill). There was no difference in hospital length of stay, development of C. difficile, or total hospital cost. CONCLUSIONS: Use of azithromycin alone or a quinolone alone for treatment of Legionella pneumonia was associated with similar hospital mortality. Few patients receive combination therapy.
BACKGROUND: Guidelines recommend azithromycin or a quinolone antibiotic for treatment of Legionella pneumonia. No clinical study has compared these strategies. METHODS: We performed a retrospective cohort analysis of adults hospitalized in the United States with a diagnosis of Legionella pneumonia in the Premier Perspectives database (1 July 2008-30 June 2013). Our primary outcome was hospital mortality; we additionally evaluated hospital length of stay, development of Clostridium difficilecolitis, and total hospital cost. We used propensity-based matching to compare patients treated with azithromycin vs a quinolone. All analyses were repeated on a subgroup of more severely ill patients, defined as requiring intensive care unit admission or mechanical ventilation or having a predicted probability of hospital mortality in the top quartile for all patients. RESULTS:Legionella pneumonia was diagnosed in 3152 adults across 437 hospitals. Quinolones alone were used in 28.8%, azithromycin alone was used in 34.0%, and 1.8% received both. Crude hospital mortality was similar: 6.6% (95% confidence interval [CI], 5.0%-8.2%) for quinolones vs 6.4% (95% CI, 5.0%-7.9%) for azithromycin (P = .87); after propensity matching (n = 813 in each group), mortality remained similar (6.3% [95% CI, 4.6%-7.9%] vs 6.5% [95% CI, 4.8%-8.2%], P = .84 for the whole cohort, and 14.9% [95% CI, 10.0%-19.8%] vs 18.3% [95% CI, 13.0%-23.6%], P = .36 for the more severely ill). There was no difference in hospital length of stay, development of C. difficile, or total hospital cost. CONCLUSIONS: Use of azithromycin alone or a quinolone alone for treatment of Legionella pneumonia was associated with similar hospital mortality. Few patients receive combination therapy.
Authors: Jacob E Simmering; Linnea A Polgreen; Douglas B Hornick; Daniel K Sewell; Philip M Polgreen Journal: Emerg Infect Dis Date: 2017-11 Impact factor: 6.883
Authors: Annie S Jasper; Jackson S Musuuza; Jessica S Tischendorf; Vanessa W Stevens; Shantini D Gamage; Fauzia Osman; Nasia Safdar Journal: Clin Infect Dis Date: 2021-06-01 Impact factor: 20.999
Authors: Holger Flick; Britt-Madelaine Arns; Josef Bolitschek; Brigitte Bucher; Katharina Cima; Elisabeth Gingrich; Sabin Handzhiev; Maximilian Hochmair; Fritz Horak; Marco Idzko; Peter Jaksch; Gabor Kovacs; Roland Kropfmüller; Bernd Lamprecht; Judith Löffler-Ragg; Michael Meilinger; Horst Olschewski; Andreas Pfleger; Bernhard Puchner; Christoph Puelacher; Christian Prior; Patricia Rodriguez; Helmut Salzer; Peter Schenk; Otmar Schindler; Ingrid Stelzmüller; Volker Strenger; Helmut Täubl; Matthias Urban; Marlies Wagner; Franz Wimberger; Angela Zacharasiewicz; Ralf Harun Zwick; Ernst Eber Journal: Wien Klin Wochenschr Date: 2020-07 Impact factor: 1.704
Authors: H Flick; B M Arns; J Bolitschek; B Bucher; K Cima; E Gingrich; S Handzhiev; M Hochmair; F Horak; M Idzko; P Jaksch; G Kovacs; R Kropfmüller; B Lamprecht; J Löffler-Ragg; M Meilinger; H Olschewski; A Pfleger; B Puchner; C Puelacher; C Prior; P Rodriguez; H Salzer; P Schenk; O Schindler; I Stelzmüller; V Strenger; H Täubl; M Urban; M Wagner; F Wimberger; A Zacharasiewicz; R H Zwick; E Eber Journal: Wien Klin Mag Date: 2020-05-18
Authors: Antoni Torres; James D Chalmers; Charles S Dela Cruz; Cristina Dominedò; Marin Kollef; Ignacio Martin-Loeches; Michael Niederman; Richard G Wunderink Journal: Intensive Care Med Date: 2019-01-31 Impact factor: 17.440